Safety and efficacy of elsubrutinib or upadacitinib alone or in combination (ABBV-599) in patients with rheumatoid arthritis and inadequate response or intolerance to biological therapies: a multicentre, double-blind, randomised, controlled, phase 2 trial

Safety and efficacy of elsubrutinib or upadacitinib alone or in combination (ABBV-599) in patients with rheumatoid arthritis and inadequate response or intolerance to biological therapies: a multicentre, double-blind, randomised, controlled, phase 2 trial

Background ABBV-599 is a novel fixed-dose combination of the Bruton's tyrosine kinase (BTK) inhibitor elsubrutinib and the Janus kinase (JAK) inhibitor upadacitinib under investigation for the treatment of autoimmune diseases. We aimed to determine whether ABBV-599 could increase the treatment...

وصف كامل

التفاصيل البيبلوغرافية
المؤلفون الرئيسيون:	Fleischmann, R, Friedman, A, Drescher, E, Singhal, A, Cortes-Maisonet, G, Doan, T, Lu, W, Wang, Z, Nader, A, Housley, W, Cohen, S, Taylor, PC, Blanco, R
التنسيق:	Journal article
اللغة:	English
منشور في:	Elsevier 2022

مواد مشابهة

Efficacy and safety of upadacitinib in patients with rheumatoid arthritis and inadequate response or intolerance to biological treatments: results through 5 years from the SELECT-BEYOND study
حسب: Roy Fleischmann, وآخرون
منشور في: (2024-07-01)

CFTR Rescue in Intestinal Organoids with GLPG/ABBV-2737, ABBV/GLPG-2222 and ABBV/GLPG-2451 Triple Therapy
حسب: Eyleen de Poel, وآخرون
منشور في: (2021-09-01)

PB2224: ABBV-744 ALONE OR IN COMBINATION WITH RUXOLITINIB OR NAVITOCLAX IN PATIENTS WITH MYELOFIBROSIS: A PHASE 1B STUDY
حسب: John Mascarenhas, وآخرون
منشور في: (2023-08-01)

Impact of upadacitinib or adalimumab as initial therapy on the achievement of 48-week treatment goals in patients with rheumatoid arthritis and inadequate response to methotrexate: Post hoc analysis of a phase 3 study
حسب: Mysler, E, وآخرون
منشور في: (2021)

The American Thoracic Society’s Spirometric Criteria Alone is Inadequate in Asthma Diagnosis
حسب: John A Gjevre, وآخرون
منشور في: (2006-01-01)

In vivo kinetics of Wolbachia depletion by ABBV-4083 in L. sigmodontis adult worms and microfilariae.
حسب: Marc P Hübner, وآخرون
منشور في: (2019-08-01)

Effectiveness of Upadacitinib in Patients with Atopic Dermatitis including those with Inadequate Response to Dupilumab and/or Baricitinib: Results from the BioDay Registry
حسب: Celeste M. Boesjes, وآخرون
منشور في: (2023-02-01)

Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT
حسب: Vibeke Strand, وآخرون
منشور في: (2019-12-01)

Correction to: Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT
حسب: Vibeke Strand, وآخرون
منشور في: (2020-06-01)

Construction services welding : examination paper no. 599 /
حسب: City and Guilds of London Institute
منشور في: ([19-)

Histerectomía laparoscópica en 1 599 pacientes
حسب: Javier Ernesto Barreras González, وآخرون

Transcriptome Analysis of Duck and Chicken Brains Infected with Aquatic Bird Bornavirus-1 (ABBV-1)
حسب: Phuc H. Pham, وآخرون
منشور في: (2022-10-01)

Upadacitinib for prurigo nodularis
حسب: Clara Muntaner-Virgili, MD, وآخرون
منشور في: (2024-06-01)

Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors
حسب: Fabrice Barlesi, وآخرون
منشور في: (2021-02-01)

Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs
حسب: Vibeke Strand, وآخرون
منشور في: (2019-12-01)

Discovery of ABBV-4083, a novel analog of Tylosin A that has potent anti-Wolbachia and anti-filarial activity.
حسب: Thomas W von Geldern, وآخرون
منشور في: (2019-02-01)

Preponderance of the oncogenic V599E and V599K mutations in <it>B-raf </it>kinase domain is enhanced in melanoma cutaneous/subcutaneous metastases
حسب: Hassanzadeh Judith, وآخرون
منشور في: (2005-06-01)

Model Informed Dosing Regimen and Phase I Results of the Anti‐PD‐1 Antibody Budigalimab (ABBV‐181)
حسب: John Powderly, وآخرون
منشور في: (2021-01-01)

Selective MCL-1 inhibitor ABBV-467 is efficacious in tumor models but is associated with cardiac troponin increases in patients
حسب: Junichiro Yuda, وآخرون
منشور في: (2023-10-01)

Upadacitinib for the treatment of psoriatic arthritis
حسب: Diogo Fonseca, وآخرون
منشور في: (2023-02-01)

P599: RARE GERMLINE VARIANTS IN ATM INFLUENCE THE PATHOGENESIS OF CLL
حسب: B. L. Lampson, وآخرون
منشور في: (2022-06-01)

PB2088: ABBV-383 IN COMBINATION WITH ANTI-CANCER REGIMENS IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: DOSE ESCALATION AND EXPANSION
حسب: Cesar Rodriguez Valdes, وآخرون
منشور في: (2023-08-01)

Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study
حسب: Joseph F Merola, وآخرون
منشور في: (2021-11-01)

1403-A PTPN2/N1 inhibitor ABBV-CLS-484 unleashes potent anti-tumor immunity
حسب: Wei Qiu, وآخرون
منشور في: (2023-11-01)

Effective treatment of alopecia universalis with oral upadacitinib
حسب: Soundos Youssef, MD, وآخرون
منشور في: (2023-01-01)

Refractory pityriasis rubra pilaris treated with upadacitinib
حسب: Eingun James Song, MD, وآخرون
منشور في: (2023-05-01)

Correction: Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study
منشور في: (2021-12-01)

Treatment of Discoid Lupus Erythematosus with Upadacitinib: A Case Report
حسب: Hu W, وآخرون
منشور في: (2023-10-01)

ABBV-744 as a potential inhibitor of SARS-CoV-2 main protease enzyme against COVID-19
حسب: Zeynab Fakhar, وآخرون
منشور في: (2021-01-01)

Immunogenicity of Sarilumab Monotherapy in Patients with Rheumatoid Arthritis Who Were Inadequate Responders or Intolerant to Disease-Modifying Antirheumatic Drugs
حسب: Alvin F. Wells, وآخرون
منشور في: (2019-05-01)

Intolerance of aloneness as a prospective predictor of suicidal ideation during COVID-19
حسب: Katie C. Lewis, وآخرون
منشور في: (2023-01-01)

Retreatment with upadacitinib in atopic dermatitis: experience in clinical practice
حسب: S. Martínez-Fernández, وآخرون
منشور في: (2023-12-01)

Management outcome(s) in eyes with retinoblastoma previously inadequately treated with systemic chemotherapy alone without focal therapy
حسب: Yacoub A Yousef, وآخرون
منشور في: (2017-01-01)

Impact of initial therapy with upadacitinib or adalimumab on achievement of 48-week treatment goals in patients with rheumatoid arthritis: post hoc analysis of SELECT-COMPARE
حسب: Mysler, E, وآخرون
منشور في: (2022)

US Patent 7,599,807 Compensating for frequency change in flowmeters
حسب: Tombs, M
منشور في: (2016)

Construction services welding (no.599) : schedules for the in-course assessment of practical work/
حسب: City and Guilds of London Institute
منشور في: ([19-)

Unilateral blaschkoid lichen planus successfully treated with upadacitinib
حسب: Chiara Rosenbaum, DO, MS, وآخرون
منشور في: (2024-03-01)

Correction: Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor inhibitors
منشور في: (2019-06-01)

Case of recalcitrant amyopathic dermatomyositis treated with upadacitinib
حسب: Albert E. Zhou, MD, PhD, وآخرون
منشور في: (2024-12-01)

Successful Treatment of Disseminated Granuloma Annulare with Upadacitinib
حسب: Axel De Greef, وآخرون
منشور في: (2024-03-01)